logo BDSP

Base documentaire

  1. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage : Economic evaluation of a phase III clinical trial in Europe and Australia.

    Article - En anglais

    This study used data from a multinational phase III randomized, double-blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox) in the treatment of aneurysmal subarachnoid hemorrhage.

    In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions.

    In women, it appeared to have no effects on costs or survival.

    Further clinical studies may provide additional information about the cost-effectiveness of this intervention.

    Mots-clés Pascal : Tirilazad, Antioxydant, Chimiothérapie, Traitement, Homme, Anévrysme, Espace sousarachnoïdien, Hémorragie, Essai clinique phase III, Analyse coût efficacité, Economie santé, Sexe, Stéroïde, Appareil circulatoire pathologie, Vaisseau sanguin pathologie

    Mots-clés Pascal anglais : Tirilazad, Antioxidant, Chemotherapy, Treatment, Human, Aneurysm, Subarachnoidal space, Hemorrhage, Phase III trial, Cost efficiency analysis, Health economy, Sex, Steroid, Cardiovascular disease, Vascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0212162

    Code Inist : 002B02N. Création : 11/09/1998.